Nelson, PT_Suppl_Table2 Supplemental Table 2. Top 20 mRNAs which were PmiT-Lys (mRNA knocked down In lysates) although not enriched in anti-AGO co-IP. mRNA -fold decrease in lysate after miR-107 transfection -fold increase in AGO-miRNP after miR-107 transfection ASF1B 9.346660554 [not enriched] CBLN2 7.888222978 SPC25 7.715050855 PHF19 7.246978764 TK1 6.867804634 HPGD 6.844472383 PLK1 6.161710924 NRG4 5.754674522 MYBL2 5.698442545 KIAA0101 5.385403093 DTL 5.38014728 GINS2 5.283503865 HSD17B13 5.233074024 CDCA8 4.891777098 CDCA5 4.802209466 EPHA4 4.782010618 FLRT3 4.759739663 CCNB1 4.733313023 HIST1H1B 4.69875648 TCF19 4.687811849
Nelson, PT_Suppl_Table3 Supplemental Table 3. Percentage of seed-containing 5’UTR, CDS, and 3’UTR sequences from top 100 PmiT-AGO and PmiT-Lys mRNAs for each of the transfected miRNAs, along with mean length of each (whether or not seed present) in nucleotides % % of top-100 PmiT-AGO with seed sequences in 5’UTR, CDS, and 3’UTR % of top-100 PmiT-Lys with seed sequences in 5’UTR, CDS, and 3’UTR 5'UTR Mean length CDS 3'UTR miR-103 10% 150.1 83% 1364.5 32% 940.8 9% 190.5 62% 1976.0 38% 1081.0 miR-107 5% 155.1 59% 1181.2 31% 872.3 7% 169.4 63% 1831.4 42% 1005.7 miR-107 MUT1 12% 196.1 45% 1358.9 2% 976.2 4% 243.3 30% 1745.2 6% 1673.2 miR-107 MUT2 152.2 64% 1506.1 994.4 183.6 56% 1854.6 40% 1027.0 miR-16 177.7 69% 1564.7 921.3 15% 183.4 58% 2021.0 22% 1010.6 miR-195 167.9 79% 1313.7 783.7 14% 188.6 1955.8 23% 1004.4 miR-320 217.8 1315.8 1520.8 232.5 47% 1530.9 1709.1